All In Biotech

Drug Trial Radar · NCT06263231

A Study to Investigate Efficacy & Safety of Intratumoral INT230-6 Compared to US Standard of Care in Adults With Soft Tissue Sarcomas (INVINCIBLE-3)

A Multicenter, Randomized, Phase 3 Study to Assess the Efficacy and Safety of INtratumorally Administered INT230-6 (SHAO, VINblastine, CIsplatin) Compared With US Standard of Care in Adults With Locally Recurrent, InoperaBLE, or Metastatic Soft Tissue Sarcomas (INVINCIBLE-3)

Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 333 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

333

Planned (sponsor's estimate)

Start

Jun 28, 2024

Primary completion

Dec 2027

Study completion Dec 2028

Sponsor

Lead sponsor
Intensity Therapeutics, Inc.Industry
Sponsor type
Industry
Collaborators
OPIS USA
First posted
Feb 16, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To compare Overall Survival (OS) for INT230-6 vs United States (US) Standard of Care (SOC) in participants with unresectable or metastatic liposarcoma, undifferentiated pleomorphic sarcoma or leiomyosarcoma who have disease progression prior to study enrollment following no more than 2 standard therapies, which must have included an anthracycline-based regimen, unless contraindicated, and then a maximum of 1 additional regimen.

Conditions

  • Sarcoma,Soft Tissue

Interventions

  • INT230-6Drug

    INT230-6 is a fixed combination of cisplatin, vinblastine and SHAO.

  • EribulinDrug

    Eribulin IV

  • TrabectedinDrug

    Trabectedin infusion

  • PazopanibDrug

    Pazopanib pill

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Survival (OS)Time frame: From date of randomization until the documented date of death from any cause for a period of up to 2 years, unless superiority is demonstrated sooner or 80% of deaths during the study period.

Locations

20 sites in 5 countries. Site status is shown where the registry gives one.

  • Mayo Clinic - Arizona

    Phoenix, Arizona · Recruiting

  • USC/Norris Comprehensive Cancer Center

    Los Angeles, California · Recruiting

  • Sarcoma Oncology Center

    Santa Monica, California · Active not recruiting

  • University of California Los Angeles (UCLA) - Santa Monica Cancer Care

    Santa Monica, California · Recruiting

  • Yale School of Medicine - Smilow Cancer Hospital - Yale - New Haven Hospital Location

    New Haven, Connecticut · Active not recruiting

  • Mayo Clinic - Florida

    Jacksonville, Florida · Recruiting

  • Profound Research LLC

    Farmington Hills, Michigan · Active not recruiting

  • Mayo Clinic - Rochester I

    Rochester, Minnesota · Recruiting

  • Nebraska Methodist Hospital

    Omaha, Nebraska · Recruiting

  • Duke Cancer Center

    Durham, North Carolina · Recruiting

  • The James Cancer Hospital and Solove Research Institute

    Columbus, Ohio · Recruiting

  • University of Pennsylvania - Abramson Cancer Center

    Philadelphia, Pennsylvania · Recruiting

  • Temple University - Fox Chase Cancer Center

    Philadelphia, Pennsylvania · Recruiting

  • Princess Margaret Cancer Centre

    Toronto, Ontario, Canada · Active not recruiting

  • Centre Leon Berard

    Lyon, France · Active not recruiting

  • Helios Klinikum Bad Saarow

    Bad Saarow, Germany · Active not recruiting

  • Universitäres Krebszentrum (UCCL)

    Leipzig, Germany · Active not recruiting

  • Hospital de la Santa Creu i Sant Pau

    Barcelona, Spain · Active not recruiting

  • Hospital Universitari Vall Hebron

    Barcelona, Spain · Active not recruiting

  • Centro Integral Oncologico Clara Campal (HM CIOCC)

    Madrid, Spain · Active not recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.